Regulatory framework for generic drugs should be revised
Ferry, S.A.
Lakartidningen 114
2017
ISSN/ISBN: 1652-7518 PMID: 28170067 Document Number: 692500
Document emailed within 1 workday
Related Documents
Beck, E.J.; Passarelli, C.; Lui, I.; Guichard, A.-C.; Simao, M.; De Lay, P.; Loures, L. 2014: Scaling-up the use of generic antiretrovirals in resource-limited countries: generic drugs for health Antiviral Therapy 19(Suppl 3): 117-123Beck, E.J.; Passarelli, C.; Lui, I.; Guichard, A.-C.; Simao, M.; De Lay, P.; Loures, L. 2014: Scaling-up the use of generic antiretrovirals in resource-limited countries: generic drugs for health Antiviral Therapy 19(Suppl 3): 117-123
White, W.T. 2014: A revised generic arrangement for the eagle ray family Myliobatidae, with definitions for the valid genera Zootaxa 3860(2): 149-166
Bangalee, V; Suleman, F 2016: Has the increase in the availability of generic drugs lowered the price of cardiovascular drugs in South Africa? Health Sa Gesondheid 21: 60-66
McGettigan, P.; Roderick, P.; Mahajan, R.; Kadam, A.; Pollock, A.M. 2015: Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs PLOS Medicine 12(5): E1001826; Discussion E1001826
1998: Quality assurance The quality assurance project undertaken by the english national board for nursing, midwifery and health visiting (ENB) has been completed, leading to a revised quality assurance framework. A publication, quality assurance manual, has been developed for ENB education staff to ensure uniform implementation of the framework throughout england, and is summarised here Nursing Standard 1987) 13(15): 41-41
Bouvenot, G.; Villani, P. 2013: Regulatory framework for prescription and recommendations for proper use La Revue du Praticien 63(8): 1165-1170
Teta, M.J.; Sielken, R.L.; Valdez-Flores, C. 1999: Ethylene oxide cancer risk assessment based on epidemiological data: application of revised regulatory guidelines Risk Analysis: An Official Publication of the Society for Risk Analysis 19(6): 1135-1155
Calcagnini, G.; Censi, F.; Bartolini, P. 2007: Electromagnetic immunity of medical devices: the European regulatory framework Annali Dell'istituto Superiore di Sanita 43(3): 268-276
Panicker, G.K.; Karnad, D.R.; Salvi, V.; Kothari, S. 2012: Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs Journal of the Association of Physicians of India 60: 56-61
Zapater, P.; Horga, J.F. 2000: Bio-equivalence and generic drugs. Studies of bio-equivalence. II. Special situations. Reflections on problems which may arise with drugs habitually used in neurology Revista de Neurologia 30(2): 146-154
Ahmed, M.U.; Björkman, M.; Lindén, M. 2015: A Generic System-Level Framework for Self-Serve Health Monitoring System through Internet of Things (IoT) Studies in Health Technology and Informatics 211: 305-307
Ayd, F.J. 1978: Generic drugs Journal of Clinical Psychiatry 39(10): 789
2002: Generic drugs. Understanding their value Mayo Clinic Health Letter 20(1): 7
García-Arieta, A.; Blázquez-Pérez, A.; de la Barrera, P.P.; Pozo-Hernández, C.; Vargas-Castrillón, E. 2006: Regarding generic antiepileptic drugs Revista de Neurologia 43(7): 446-8; Author Reply 448
Mack, R.B. 1988: Concern about generic drugs North Carolina Medical Journal 49(12): 665
Worth, T. 2015: The rising cost of generic drugs Medical Economics 92(5): 36-39
Reiffel, J.A. 2001: Issues in the use of generic antiarrhythmic drugs Current Opinion in Cardiology 16(1): 23-29
Marx, G.F. 1990: Trade and generic names of drugs New York State Journal of Medicine 90(10): 517
Taylor, J.M. 1978: Color scheme for generic drugs New England Journal of Medicine 298(20): 1152